LT - Riluzolo, riluzolo provaistų arba riluzolo analogų naudojimas kartu su imunoterapijos rūšimis vėžio formų gydymui
EN - USE OF RILUZOLE, RILUZOLE PRODRUGS OR RILUZOLE ANALOGS WITH IMMUNOTHERAPIES TO TREAT CANCERS
Legal status
Patent in force
Bibliographic data
Indications of the International Patent Classification (IPC)
| (51) |
INT.CL. |
A61K 31/428 |
(2006.01) |
|
|
C07D 277/82 |
(2006.01) |
|
|
A61P 35/00 |
(2006.01) |
European patent
| (11) |
Number of the document |
4019019 |
| (13) |
Kind of document |
T |
| (96) |
European patent application number |
21207246.6 |
|
Date of filing the European patent application |
2017-05-19 |
| (97) |
Date of publication of the European application |
2022-06-29 |
| (45) |
Date of publication and mention of the grant of the patent |
2024-02-07
|
| (46) |
Date of publication of the claims translation |
2024-06-25
|
Priority applications
| (30) |
Number |
Date |
Country code |
|
201662339433 P |
2016-05-20
|
US |
Inventors
| (72) |
CORIC, Vladimir , US
|
Grantee
| (73) |
Biohaven Therapeutics Ltd. ,
215 Church Street, New Haven, CT 06510,
US
|
Attorney or representative
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
Title
| (54) |
Riluzolo, riluzolo provaistų arba riluzolo analogų naudojimas kartu su imunoterapijos rūšimis vėžio formų gydymui |
| |
USE OF RILUZOLE, RILUZOLE PRODRUGS OR RILUZOLE ANALOGS WITH IMMUNOTHERAPIES TO TREAT CANCERS |
Last renewal fee
|
Payment date |
Validity (years) |
Amount |
|
2025-04-22 |
9 |
208.00
EUR
|
Next renewal fee
|
2026-05-19 |
